Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Background: Neutralizing mAbs can prevent communicable viral diseases. MK-1654 is a respiratory syncytial virus (RSV) F glycoprotein neutralizing monoclonal antibody (mAb) under development to prevent RSV infection in infants. Development and validation of methods to predict efficacious doses of neu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brian M. Maas, Jos Lommerse, Nele Plock, Radha A. Railkar, S.Y. Amy Cheung, Luzelena Caro, Jingxian Chen, Wen Liu, Ying Zhang, Qinlei Huang, Wei Gao, Li Qin, Jie Meng, Han Witjes, Emilie Schindler, Benjamin Guiastrennec, Francesco Bellanti, Daniel S. Spellman, Brad Roadcap, Mariya Kalinova, Juin Fok-Seang, Andrew P. Catchpole, Amy S. Espeseth, S. Aubrey Stoch, Eseng Lai, Kalpit A. Vora, Antonios O. Aliprantis, Jeffrey R. Sachs
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Respiratory Syncytial Virus Monoclonal Antibody RSV, Meta-analysis Modelling and Simulation Human Challenge Study Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/29110f874edd46dea00e331b42ac8484
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis

Ejemplares similares